Commodore Capital »

Erasca shares owned by Commodore Capital

Quarter-by-quarter ownership of Erasca (ERAS) shares owned by Commodore Capital from 13F filings

Historical chart of Commodore Capital investment in Erasca

Tip: Access up to 7 years of quarterly data

All positions including Erasca held by Commodore Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Erasca by Commodore Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $51M 3.2M 16.18

More positions owned by Commodore Capital

Relay Therapeutics (RLAY)
Alkermes SHS (ALKS)
Enliven Therapeutics (ELVN)
Cogent Biosciences (COGT)
Spyre Therapeutics Com New (SYRE)
Tyra Biosciences (TYRA)
Celldex Therapeutics Com New (CLDX)
Nuvalent Inc-a (NUVL)
Amylyx Pharmaceuticals (AMLX)
Kymera Therapeutics (KYMR)
Alto Neuroscience Com Shs (ANRO)
Pharvaris N V (PHVS)
Erasca (ERAS)
Damora Therapeutics Com New (DMRA)
Xenon Pharmaceuticals (XENE)

View all positions for Commodore Capital

Top funds holding Erasca

Frazier Life Sciences Management
BlackRock
VR Adviser
T. Rowe Price Investment Management
Vanguard Group
Vivo Capital
Vanguard Capital Management
Logos Global Management
Paradigm Biocapital Advisors
Siren
Arch Venture Corp
State Street Corporation
Geode Capital Management
Cormorant Asset Management
Balyasny Asset Management

View all funds holding Erasca